cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.14559301.v1
title: Additional file 4 of EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer

description: Additional file 4: Table S4–S7. List of positive/negative gene set for BRCA and MBCA. Table S8–S10. Homo_sapiens genes for BRCA and MBCA
DOI: 10.6084/m9.figshare.14559307
title: Additional file 6 of EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer

description: Additional file 6: Table S13–S26. The list of mutated genes extracted by software tools for BRCA and MBCA, and comparison among these genes (p value ≤ 0.05) for MBCA
DOI: 10.6084/m9.figshare.14559307.v1
title: Additional file 6 of EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer

description: Additional file 6: Table S13–S26. The list of mutated genes extracted by software tools for BRCA and MBCA, and comparison among these genes (p value ≤ 0.05) for MBCA
DOI: 10.6084/m9.figshare.14559292.v1
title: Additional file 2 of EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer

description: Additional file 2: Table S2 and S3. The original mutation files for metastasis breast tumors
DOI: 10.6084/m9.figshare.14559310.v1
title: Additional file 7 of EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer

description: Additional file 7: Table S27–S31. The list of driver and passenger genes of four learning machines for MBCA
DOI: 10.6084/m9.figshare.14559310
title: Additional file 7 of EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer

description: Additional file 7: Table S27–S31. The list of driver and passenger genes of four learning machines for MBCA
DOI: 10.6084/m9.figshare.14559313.v1
title: Additional file 8 of EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer

description: Additional file 8: Table S32–S41. The comparison of drivers predicted by all machine learning methods for MBCA
DOI: 10.6084/m9.figshare.14559316
title: Additional file 9 of EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer

description: Additional file 9: Table S42. The list of driver genes of EARN for MBCA that have been cited in 108 studies of HCMDB. Table S43. The list of novel genes predicted by EARN50 for MBCA. Table S44. The comparison of top 50 predictions of EARN and four software tools for BRCA. Table S45. The comparison among the performance of classifier pairs based on K-fold cross-validated paired t-test.
DOI: 10.6084/m9.figshare.14559316.v1
title: Additional file 9 of EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer

description: Additional file 9: Table S42. The list of driver genes of EARN for MBCA that have been cited in 108 studies of HCMDB. Table S43. The list of novel genes predicted by EARN50 for MBCA. Table S44. The comparison of top 50 predictions of EARN and four software tools for BRCA. Table S45. The comparison among the performance of classifier pairs based on K-fold cross-validated paired t-test.
DOI: 10.6084/m9.figshare.14559311
title: Additional file 2 of Genetic diversity and population structure of date palms (Phoenix dactylifera L.) in Ethiopia using microsatellite markers

description: Additional file 2: Table 2 Microsatellite genotypic data of 124 date palm genotypes using 10 SSR markers.
DOI: 10.6084/m9.figshare.14559313
title: Additional file 8 of EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer

description: Additional file 8: Table S32–S41. The comparison of drivers predicted by all machine learning methods for MBCA
DOI: 10.6084/m9.figshare.14559308.v1
title: Additional file 1 of Genetic diversity and population structure of date palms (Phoenix dactylifera L.) in Ethiopia using microsatellite markers

description: Additional file 1: Table 1 Data information of date palms in Ethiopia during the time of sample collection and cods of samples that were used for analysis.
DOI: 10.6084/m9.figshare.14559314
title: Additional file 3 of Genetic diversity and population structure of date palms (Phoenix dactylifera L.) in Ethiopia using microsatellite markers

description: Additional file 3: Table 3 Proportion of individuals assigned in each DAPC cluster.
DOI: 10.6084/m9.figshare.14559311.v1
title: Additional file 2 of Genetic diversity and population structure of date palms (Phoenix dactylifera L.) in Ethiopia using microsatellite markers

description: Additional file 2: Table 2 Microsatellite genotypic data of 124 date palm genotypes using 10 SSR markers.
DOI: 10.6084/m9.figshare.14559308
title: Additional file 1 of Genetic diversity and population structure of date palms (Phoenix dactylifera L.) in Ethiopia using microsatellite markers

description: Additional file 1: Table 1 Data information of date palms in Ethiopia during the time of sample collection and cods of samples that were used for analysis.
DOI: 10.6084/m9.figshare.14559314.v1
title: Additional file 3 of Genetic diversity and population structure of date palms (Phoenix dactylifera L.) in Ethiopia using microsatellite markers

description: Additional file 3: Table 3 Proportion of individuals assigned in each DAPC cluster.
DOI: 10.6084/m9.figshare.14558935
title: Additional file 3 of Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte

description: Additional file 3: Figure S3. Mass spectra of the triply charged hACE2 tryptic peptide 466-475 in the glycated (panel A) and non-glycated (panel B) form. hACE2 is for human Angiotensin Converting enzyme 2 type.
DOI: 10.6084/m9.figshare.14559320
title: Additional file 4 of Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte

description: Additional file 4: Figure S4. Mass spectra of the triply charged hACE2 tryptic peptide 560-577 in the glycated (panel A) and non-glycated (panel B) form. hACE2 is for human Angiotensin Converting enzyme 2 type.
DOI: 10.6084/m9.figshare.14558935.v1
title: Additional file 3 of Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte

description: Additional file 3: Figure S3. Mass spectra of the triply charged hACE2 tryptic peptide 466-475 in the glycated (panel A) and non-glycated (panel B) form. hACE2 is for human Angiotensin Converting enzyme 2 type.
DOI: 10.6084/m9.figshare.14559320.v1
title: Additional file 4 of Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte

description: Additional file 4: Figure S4. Mass spectra of the triply charged hACE2 tryptic peptide 560-577 in the glycated (panel A) and non-glycated (panel B) form. hACE2 is for human Angiotensin Converting enzyme 2 type.
DOI: 10.5517/ccdc.csd.cc26twwt
title: CCDC 2050677: Experimental Crystal Structure Determination

description: Related Article: Daniel Komisarek, Marc Pallaske, Vera Vasylyeva|2021|Z.Anorg.Allg.Chem.|647|984|doi:10.1002/zaac.202100012
DOI: 10.5517/ccdc.csd.cc26twxv
title: CCDC 2050678: Experimental Crystal Structure Determination

description: Related Article: Daniel Komisarek, Marc Pallaske, Vera Vasylyeva|2021|Z.Anorg.Allg.Chem.|647|984|doi:10.1002/zaac.202100012
DOI: 10.5281/zenodo.4742786
title: Datasets for ``Collision fluctuations of lucky droplets with superdroplets''

description: <pre>This directory contains an index.html file with links to the run directories and idl plotting routines with secondary data for the other figures for the paper "Collision fluctuations of lucky droplets with superdroplets" by Xiang-Yu Li, Bernhard Mehlig, Gunilla Svensson, Axel Brandenburg, and Nils E. L. Haugen. If anything turns out to be incomplete, please email brandenb@nordita.org.</pre>
DOI: 10.5281/zenodo.4742785
title: Datasets for ``Collision fluctuations of lucky droplets with superdroplets''

description: <pre>This directory contains an index.html file with links to the run directories and idl plotting routines with secondary data for the other figures for the paper "Collision fluctuations of lucky droplets with superdroplets" by Xiang-Yu Li, Bernhard Mehlig, Gunilla Svensson, Axel Brandenburg, and Nils E. L. Haugen. If anything turns out to be incomplete, please email brandenb@nordita.org.</pre>
DOI: 10.6084/m9.figshare.8858552
title: Evaluating and reducing xerosis in competitive swimmers: an in vitro study and randomized controlled clinical trial

description: Xerosis is a common problem with significant sequelae in competitive swimmers, and it results from transepidermal water loss. This study evaluates moisture barriers for reducing xerosis in competitive swimmers. An artificial skin model was used to evaluate five products. Models were measured for changes in thickness and weight over 7 days. The optimal barrier was tested in a randomized controlled trial (RCT) of 20 swimmers. Skin moisture content was serially measured. Skin micrographs were scored in a blinded fashion. The moisture barrier #1 treated skin model at day 7 maintained a mean thickness of 7.08 mm versus 2.38 mm for control (<i>p</i> = .0001). The mean weights of group 1 treated and control groups at day 7 were 40.1 and 8.65 g (<i>p</i> = .03). In the RCT, the group treated with moisture barrier #1 and the controls exhibited low moisture content and moderate xerosis scores at baseline. At week 3, moisture measurements for treated and control groups were 28.6% and 18.2% (<i>p</i> = .003). The mean xerosis scores for the treated and control groups were 8.5 and 12.9 (<i>p</i> = .0008). Artificial skin preservation varied for five commercially available moisture barriers. Moisture barrier application improved moisture content and reduced xerosis in competitive swimmers.
DOI: 10.6084/m9.figshare.8858552.v1
title: Evaluating and reducing xerosis in competitive swimmers: an in vitro study and randomized controlled clinical trial

description: Xerosis is a common problem with significant sequelae in competitive swimmers, and it results from transepidermal water loss. This study evaluates moisture barriers for reducing xerosis in competitive swimmers. An artificial skin model was used to evaluate five products. Models were measured for changes in thickness and weight over 7 days. The optimal barrier was tested in a randomized controlled trial (RCT) of 20 swimmers. Skin moisture content was serially measured. Skin micrographs were scored in a blinded fashion. The moisture barrier #1 treated skin model at day 7 maintained a mean thickness of 7.08 mm versus 2.38 mm for control (<i>p</i> = .0001). The mean weights of group 1 treated and control groups at day 7 were 40.1 and 8.65 g (<i>p</i> = .03). In the RCT, the group treated with moisture barrier #1 and the controls exhibited low moisture content and moderate xerosis scores at baseline. At week 3, moisture measurements for treated and control groups were 28.6% and 18.2% (<i>p</i> = .003). The mean xerosis scores for the treated and control groups were 8.5 and 12.9 (<i>p</i> = .0008). Artificial skin preservation varied for five commercially available moisture barriers. Moisture barrier application improved moisture content and reduced xerosis in competitive swimmers.
DOI: 10.6084/m9.figshare.14558820
title: 2021 JGR Solid Earth Hybrid Wave Numerical Simulation

description: The files includes all the parameters used for the numerical simulation and visualisation.
DOI: 10.6084/m9.figshare.14558820.v1
title: 2021 JGR Solid Earth Hybrid Wave Numerical Simulation

description: The files includes all the parameters used for the numerical simulation and visualisation.
DOI: 10.6084/m9.figshare.13919640
title: Antiviral use is associated with a decrease in the rate of influenza-related complications, health care resource utilization, and costs

description: To determine the effect of antiviral agents on influenza-related complications, health care resource utilization (HRU), and costs over three influenza seasons (2014–2016). This retrospective cohort study used claims data from the U.S. MarketScan Research Databases. Patients with a diagnosis code for influenza during the 2014–2016 seasons in an outpatient setting, with continuous enrollment from 1 year before to 91 d after diagnosis, were included. Patients who received an antiviral within 48 h of diagnosis were identified and propensity score–matched to a comparator cohort of untreated patients on baseline demographics, comorbid conditions, and HRU. Outcomes were assessed at days 30 and 90 after diagnosis and included respiratory-related complications (all respiratory-related and selected respiratory-related conditions [influenza, asthma, chronic obstructive pulmonary disease, or infection]), HRU, and costs. Treated and matched untreated cohorts each consisted of 362,818 patients. HRU was significantly lower in the treated cohort compared with the untreated cohort at 30 and 90 d after diagnosis, respectively (hospitalizations: 0.6% <i>vs.</i> 0.8% and 1.2% <i>vs.</i> 1.6%; emergency department [ED] visits: 4.1% <i>vs.</i> 4.9% and 7.9% <i>vs.</i> 9.2%; intensive care unit/critical care unit (ICU/CCU) admissions: 0.2% <i>vs.</i> 0.4% and 0.4% <i>vs.</i> 0.6%). Respiratory-related HRU was lower in the treated cohort at both 30 and 90 d after diagnosis (<i>p</i> vs. $778; day 90: $1778 <i>vs.</i> $2119), despite higher prescription costs in the treated group. The study was retrospective and subject to residual selection bias, despite propensity score matching. Additionally, despite its potential relevance to influenza severity, vaccination status was not available in our data. Antiviral influenza treatment is associated with a significant reduction in complications, HRU, and costs at 30 and 90 d after diagnosis.
DOI: 10.6084/m9.figshare.13919640.v2
title: Antiviral use is associated with a decrease in the rate of influenza-related complications, health care resource utilization, and costs

description: To determine the effect of antiviral agents on influenza-related complications, health care resource utilization (HRU), and costs over three influenza seasons (2014–2016). This retrospective cohort study used claims data from the U.S. MarketScan Research Databases. Patients with a diagnosis code for influenza during the 2014–2016 seasons in an outpatient setting, with continuous enrollment from 1 year before to 91 d after diagnosis, were included. Patients who received an antiviral within 48 h of diagnosis were identified and propensity score–matched to a comparator cohort of untreated patients on baseline demographics, comorbid conditions, and HRU. Outcomes were assessed at days 30 and 90 after diagnosis and included respiratory-related complications (all respiratory-related and selected respiratory-related conditions [influenza, asthma, chronic obstructive pulmonary disease, or infection]), HRU, and costs. Treated and matched untreated cohorts each consisted of 362,818 patients. HRU was significantly lower in the treated cohort compared with the untreated cohort at 30 and 90 d after diagnosis, respectively (hospitalizations: 0.6% <i>vs.</i> 0.8% and 1.2% <i>vs.</i> 1.6%; emergency department [ED] visits: 4.1% <i>vs.</i> 4.9% and 7.9% <i>vs.</i> 9.2%; intensive care unit/critical care unit (ICU/CCU) admissions: 0.2% <i>vs.</i> 0.4% and 0.4% <i>vs.</i> 0.6%). Respiratory-related HRU was lower in the treated cohort at both 30 and 90 d after diagnosis (<i>p</i> vs. $778; day 90: $1778 <i>vs.</i> $2119), despite higher prescription costs in the treated group. The study was retrospective and subject to residual selection bias, despite propensity score matching. Additionally, despite its potential relevance to influenza severity, vaccination status was not available in our data. Antiviral influenza treatment is associated with a significant reduction in complications, HRU, and costs at 30 and 90 d after diagnosis.
DOI: 10.6084/m9.figshare.13919640.v1
title: Antiviral Use Is Associated with a Decrease in the Rate of Influenza-Related Complications, Health Care Resource Utilization, and Costs

description: To determine the effect of antiviral agents on influenza-related complications, healthcare resource utilization (HRU), and costs over 3 influenza seasons (2014-2016). This retrospective cohort study used claims data from the U.S. MarketScan Research Databases. Patients with a diagnosis code for influenza during the 2014-2016 seasons in an outpatient setting, with continuous enrollment from 1 year before to 91 days after diagnosis, were included. Patients who received an antiviral within 48 hours of diagnosis were identified and propensity score–matched to a comparator cohort of untreated patients on baseline demographics, comorbid conditions, and HRU. Outcomes were assessed at days 30 and 90 after diagnosis and included respiratory-related complications (all respiratory-related and selected respiratory-related conditions [influenza, asthma, chronic obstructive pulmonary disease, or infection]), HRU, and costs. Treated and matched untreated cohorts each consisted of 362,818 patients. HRU was significantly lower in the treated cohort compared with the untreated cohort at 30 and 90 days after diagnosis, respectively (hospitalizations: 0.6% vs 0.8% and 1.2% vs 1.6%; emergency department [ED] visits: 4.1% vs 4.9% and 7.9% vs 9.2%; intensive care/critical care unit admissions: 0.2% vs 0.4% and 0.4% vs 0.6%). Respiratory-related HRU was lower in the treated cohort at both 30 and 90 days after diagnosis (P &lt; 0.0001 for both periods). Mean all-cause total costs (including prescription costs) were significantly reduced in the treated group (day 30: $633 vs $778; day 90: $1778 vs $2119), despite higher prescription costs in the treated group. The study was retrospective and subject to residual selection bias, despite propensity score matching. Additionally, despite its potential relevance to influenza severity, vaccination status was not available in our data. Antiviral influenza treatment is associated with a significant reduction in complications, HRU, and costs at 30 and 90 days after diagnosis.
DOI: 10.6084/m9.figshare.12962672
title: Comparison of hospital length of stay of acute ischemic stroke patients with non-valvular atrial fibrillation started on rivaroxaban or warfarin treatment during hospitalization

description: To compare the hospital length of stay (LOS) between rivaroxaban and warfarin in hospitalized acute stroke patients with non-valvular atrial fibrillation (NVAF) in Japan. This was a retrospective, observational study using a Japanese hospital claims database. Data of NVAF patients who were started on oral anticoagulant (OAC) treatment during hospitalization were extracted and LOS-OAC (period from the initiation of index OAC therapy to the end of hospitalization or censoring date) and medical costs were compared between rivaroxaban and warfarin treatments. To compare LOS-OAC, a time-to-event analysis was performed using the Kaplan–Meier method. The analysis period was from April 2012 to December 2015. This study included 773 rivaroxaban users and 1077 warfarin users. After the propensity score matching, 546 patients for each treatment constituted the matched cohorts. Although the rivaroxaban users had a similar LOS-OAC to warfarin users (median, 18 vs. 19 days, <i>p</i> = .657) in the matched cohorts, 3 days shorter LOS-OAC was observed in the rivaroxaban users (median, 17 vs. 20 days, <i>p</i> = .043) after IPTW adjustment. Subgroup analysis by the severity of stroke after IPTW adjustment demonstrated that rivaroxaban users had a shorter LOS-OAC than warfarin users among patients with mild (median, 10 vs. 14 days) and moderate stroke severity (22 vs. 27 days), but not among those with severe stroke severity (26 vs. 25 days). It is not possible to say that the only confounder was stroke severity and therefore other possible known and unknown confounders could not be ruled out. The rivaroxaban users had a 3-day shorter LOS-OAC after IPTW-adjustment. Using rivaroxaban was associated with 4–5 days shorter LOS-OAC than using warfarin in patients with mild or moderate stroke, though treatment selection did not have a large impact in patients with severe stroke.
DOI: 10.6084/m9.figshare.12962672.v1
title: Comparison of hospital length of stay of acute ischemic stroke patients with non-valvular atrial fibrillation started on rivaroxaban or warfarin treatment during hospitalization

description: To compare the hospital length of stay (LOS) between rivaroxaban and warfarin in hospitalized acute stroke patients with non-valvular atrial fibrillation (NVAF) in Japan. This was a retrospective, observational study using a Japanese hospital claims database. Data of NVAF patients who were started on oral anticoagulant (OAC) treatment during hospitalization were extracted and LOS-OAC (period from the initiation of index OAC therapy to the end of hospitalization or censoring date) and medical costs were compared between rivaroxaban and warfarin treatments. To compare LOS-OAC, a time-to-event analysis was performed using the Kaplan–Meier method. The analysis period was from April 2012 to December 2015. This study included 773 rivaroxaban users and 1077 warfarin users. After the propensity score matching, 546 patients for each treatment constituted the matched cohorts. Although the rivaroxaban users had a similar LOS-OAC to warfarin users (median, 18 vs. 19 days, <i>p</i> = .657) in the matched cohorts, 3 days shorter LOS-OAC was observed in the rivaroxaban users (median, 17 vs. 20 days, <i>p</i> = .043) after IPTW adjustment. Subgroup analysis by the severity of stroke after IPTW adjustment demonstrated that rivaroxaban users had a shorter LOS-OAC than warfarin users among patients with mild (median, 10 vs. 14 days) and moderate stroke severity (22 vs. 27 days), but not among those with severe stroke severity (26 vs. 25 days). It is not possible to say that the only confounder was stroke severity and therefore other possible known and unknown confounders could not be ruled out. The rivaroxaban users had a 3-day shorter LOS-OAC after IPTW-adjustment. Using rivaroxaban was associated with 4–5 days shorter LOS-OAC than using warfarin in patients with mild or moderate stroke, though treatment selection did not have a large impact in patients with severe stroke.